An economist by training with a lengthy career in medtech and pharma, Benedikt von Braunmühl is well placed to provide a candid view of the contract development and manufacturing market. He took the helm of Rentschler Biopharma SE in September 2023 after the departure of Frank Mathias earlier in the year, who is now CEO of Oxford BioMedica plc.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?